Xiao-Ye He

Fudan University, Shanghai, Shanghai Shi, China

Are you Xiao-Ye He?

Claim your profile

Publications (4)7.57 Total impact

  • Yan-Ying Wang · Tao Ren · Ying-Yun Cai · Xiao-Ye He ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract MicroRNAs are closely linked to tumor metastasis and let-7a may play a role in inhibiting the proliferation, invasion, and metastasis of lung cancer. In vitro, we aim to observe the impact of let-7a on the proliferation and invasion of the nonsmall cell lung cancer cell line 95D by constructing a lentiviral vector that expresses let-7a. Cell proliferation assays and Transwell experiments were used to compare the proliferation and invasion of the 95D cell group with let-7a overexpressed or inhibited. Real-time polymerase chain reaction and immunoblotting analysis were used to compare the expression of K-RAS and HMGA2 at mRNA and the protein level in the above groups. The results showed the cells in the let-7a overexpressed group were significantly less proliferative and invasive than those in the let-7a inhibited group (p<0.05). K-RAS and HMGA2 mRNA levels were significantly higher in the let-7a overexpressed group than those in the let-7a inhibited group (p<0.05). However, the protein levels of K-RAS and HMGA2 were significantly lower in the let-7a overexpressed group than those in the let-7a inhibited group (p<0.05). We suppose that let-7a inhibits the proliferation and invasion of the cell line 95D by regulating the translation of K-RAS and HMGA2 mRNA, not the transcription of the mRNA itself.
    Cancer Biotherapy & Radiopharmaceuticals 11/2012; 28(2). DOI:10.1089/cbr.2012.1307 · 1.78 Impact Factor
  • Xiao-ye He · Xiao-long Zhao · Qian Gu · Ji-ping Shen · Yu Hu · Ren-ming Hu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Calorie restriction (CR) is a simple method for delaying aging process, extending lifespan, and preventing the onset of aging-related diseases, such as diabetes. However, the mechanism, by which CR influences β-cell functions during the aging process, still remains unclear. In this study, sixteen 8-week-old male Sprague-Dawley rats were randomized to control group with food intake ad libitum and CR group fed with 70% of food intake of the control group. Twenty-four weeks later, the body weights of the rats with CR were significantly lower with the smaller amounts of perirenal and epididymal fats, compared to those of control rats. The β-cell activity, as judged by the early insulin secretion in the intraperitoneal glucose tolerance test, was significantly higher in the CR group than that in control animals. Moreover, CR animals showed the increased β-cell mass and proliferation of β-cells in pancreas. The plasma level of malondialdehyde was lower in CR rats than that in control rats, while the activities of superoxide dismutase, catalase and glutathione peroxidase in plasma were higher in CR rats than control rats. These results indicate that aging is associated with the increases in oxidative stress, which was, however, alleviated by CR. In conclusion, CR from a young age preserves the principal β-cell function of early insulin secretion in rats probably by stimulating the β-cell proliferation. Our observations provide the evidence for clinical significance of CR in preventing β-cell dysfunction during the aging process, which may delay the onset of aging-related disease, including diabetes in humans.
    The Tohoku Journal of Experimental Medicine 08/2012; 227(4):245-52. DOI:10.1620/tjem.227.245 · 1.35 Impact Factor
  • Source
    Tao Ren · Xiao-Ye He · Ying-Yun Cai · Yan-Ying Wang ·
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the role of miRNA expression profile in the increased invasiveness of non-small cell lung cancer (NSCLC) 95D cells upon TLR9 agonist stimulation, miRNA microarray assay was performed to detect the expression profile of miRNA in NSCLC 95D cells with or without treatment of CpG oligodeoxynucleotide (ODN). Real time PCR was performed in twenty NSCLC samples and corresponding normal tissues to verify the expressions of target miRNA. The miRNA microarray assay showed that CpG ODN stimulation alternated the miRNA expression profile in NSCLC 95D cells and the difference in the expressions of 23 miRNAs between the CpG ODN treated group and untreated group was at least two-fold, among which 20 miRNAs were down-regulated. The down-regulation of let-7a was the most significant, which was also confirmed by Real time PCR. We concluded that TLR9 agonist might raise the invasiveness of NSCLC 95D cells by alternating the expression profile of miRNA, especially the down-regulation of let-7a.
    Scientific research and essays 06/2011; 6(12). · 0.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to observe the variation of CD4(+)CD25(+) regulatory T cells in periphery blood and tumor microenvironment of non-small cell lung cancer (NSCLC) patients and the effects of CpG ODN. The proportion of CD4(+)CD25(+) regulatory T cells, Foxp3 gene expression, levels of tumor growth factor-β (TGF-β) and immunoreactive fibronectin-γ (IFN-γ) in the periphery blood of 30 NSCLC patients and 30 healthy volunteers were compared. These indicators were compared before and after CpG ODN treatment. Foxp3 gene expression in the tumor microenvironment of NSCLC patients was also observed. The results showed CD4(+)CD25(+) regulatory T cell proportion, Foxp3 expression and TGF-β levels in the periphery blood of NSCLC patients were higher than those of healthy volunteers (p < 0.05), and these indicators of patients were significantly decreased after CpG ODN 2006 treatment (p < 0.05). Foxp3 expression in the metastatic lymph nodes was higher than that in the non-metastatic ones of NSCLC patients (p = 0.000). In conclusion, a rise in the proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells was demonstrated in the periphery blood and tumor microenvironments of NSCLC patients. CpG ODN 2006 downregulated the CD4(+)CD25(+)Foxp3(+) regulatory T cells proportion and TGF-β levels in the periphery blood of these patients.
    Targeted Oncology 05/2011; 6(3):147-54. DOI:10.1007/s11523-011-0182-9 · 4.00 Impact Factor